C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation [PDF]
, 2015 Complement C1q is the activator of the classical pathway. However, it is now recognized that C1q can exert functions unrelated to complement activation.
Agostinis, C +9 more
core +3 more sources
Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder [PDF]
, 2016 Background: Multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD) are autoimmune demyelinating diseases distinguished clinically by selective involvement in NMOSD of optic nerves and spinal cord. Early clinical manifestations are
Evans, David R. S. +6 more
core +1 more source
Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody.
PLoS ONE, 2018 Modulating the complement system is a promising strategy in drug discovery for disorders with uncontrolled complement activation. Although some of these disorders can be effectively treated with an antibody that inhibits complement C5, the high plasma ...
Zenjiro Sampei +15 more
doaj +1 more source
Computational and Structural Biotechnology Journal, 2023 Human complement is the first line of defence against invading pathogens and is involved in tissue homeostasis. Complement-targeted therapies to treat several diseases caused by a dysregulated complement are highly desirable.
Natalia Ruiz-Molina +3 more
doaj +1 more source
Complement C3 variant and the risk of age-related macular degeneration [PDF]
, 2007 Background: Age-related macular degeneration is the most common cause of blindness in Western populations. Susceptibility is influenced by age and by genetic and environmental factors.
Armbrecht, AM +16 more
core +1 more source
Translational Psychiatry, 2023 Immunological/inflammatory factors are implicated in the development of psychosis. Complement is a key driver of inflammation; however, it remains unknown which factor is better at predicting the onset of psychosis.
TianHong Zhang +12 more
doaj +1 more source
Pharmacological management of immune and oxidative disturbances in patients with encephalopathy on the background of hypertension [PDF]
, 2016 Inclusion of a comprehensive drug treatment of patients with discirculatory encephalopathy cerebrolysin combination with meksidol normalizes the concentration of C3 and C4 components of the complement system, IgG, malondialdehyde, catalase activity ...
Bistrova, N. A. +2 more
core +2 more sources
Complement C5-blocking Agent in Refractory Dermatomyositis [PDF]
The Journal of Rheumatology, 2018 Dermatomyositis (DM) is a rare autoimmune disease that belongs to the group of idiopathic inflammatory myopathies (IIM). The usual treatment of DM was based on steroids, methotrexate, and azathioprine. Intravenous immunoglobulin (IVIG), rituximab (RTX), or other biological treatments recently emerged as steroid-sparing agents1.
STANISLAS FAGUER +2 more
openaire +1 more source
Complement C3dg-mediated erythrophagocytosis: Implications for paroxysmal nocturnal hemoglobinuria [PDF]
, 2015 The clinical management of paroxysmal nocturnal hemoglobinuria (PNH), a rare but life-threatening hematologic disease, has fundamentally improved with the introduction of a therapeutic that prevents complement-mediated intravascular hemolysis. However, a
Koutsogiannaki, Sophia +6 more
core +1 more source
Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment [PDF]
, 2017 Los datos asociados con este artículo están disponibles en: http://dx.doi.org/10.1016/j.imbio.2016.09.002.Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hemolytic anemia characterized by complement-mediated intravascular hemolysis that is ...
Anter, Jaouad +10 more
core +2 more sources